MedTrace Logo

Naltrexone for Impulse Control Disorders in Parkinson's Disease

NCT01052831 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2015-08-06

Study results available
· View outcomes & findings →

Summary

This study will evaluate the effectiveness of naltrexone in reducing ICD symptoms in Parkinson's disease patients taking a dopamine agonist.

Conditions

  • Impulse Control Disorder
  • Parkinson Disease

Interventions

DRUG

Naltrexone

50-100 mg qd for 8 weeks

DRUG

Placebo

50-100 mg qd for 8 weeks

Sponsors & Collaborators

Principal Investigators

  • Daniel Weintraub, MD · University of Pennsylvania

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01052831 on ClinicalTrials.gov